Beam Therapeutics (BEAM) Enterprise Value: 2019-2025
Historic Enterprise Value for Beam Therapeutics (BEAM) over the last 7 years, with Sep 2025 value amounting to $1.4 billion.
- Beam Therapeutics' Enterprise Value rose 26.23% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.8 billion, marking a year-over-year increase of 16.30%. This contributed to the annual value of $1.2 billion for FY2024, which is 16.93% up from last year.
- As of Q3 2025, Beam Therapeutics' Enterprise Value stood at $1.4 billion, which was up 146.41% from $560.1 million recorded in Q2 2025.
- In the past 5 years, Beam Therapeutics' Enterprise Value registered a high of $6.3 billion during Q2 2021, and its lowest value of $414.5 million during Q1 2025.
- In the last 3 years, Beam Therapeutics' Enterprise Value had a median value of $1.1 billion in 2024 and averaged $1.1 billion.
- In the last 5 years, Beam Therapeutics' Enterprise Value surged by 581.75% in 2021 and then plummeted by 74.15% in 2025.
- Beam Therapeutics' Enterprise Value (Quarterly) stood at $4.9 billion in 2021, then slumped by 65.54% to $1.7 billion in 2022, then slumped by 38.69% to $1.0 billion in 2023, then grew by 16.93% to $1.2 billion in 2024, then climbed by 26.23% to $1.4 billion in 2025.
- Its Enterprise Value stands at $1.4 billion for Q3 2025, versus $560.1 million for Q2 2025 and $414.5 million for Q1 2025.